If you've come across headlines about GLP-1 medications and heart health, you may have run into two different angles: a relatively new FDA approval tied to reducing cardiovascular risk, and a note in prescribing information about these medications causing a faster resting heart rate as a side effect. Both are accurate, and they describe different things, so it's worth separating them with sourced, specific information rather than blending them into one vague impression.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why heart health comes up in conversations about GLP-1 medications
GLP-1 receptor agonists such as semaglutide were first developed for type 2 diabetes and are now also used, in certain formulations, for chronic weight management. Both obesity and type 2 diabetes are established risk factors for cardiovascular disease, according to the American Diabetes Association and the Centers for Disease Control and Prevention, so it makes sense that researchers have studied whether a medication that affects appetite and blood sugar regulation might also affect cardiovascular outcomes.
Because so many people who use GLP-1 medications also carry some degree of cardiovascular risk, whether from excess weight, blood pressure, cholesterol, or a prior cardiac event, heart health tends to come up naturally in conversations with a prescribing clinician, independent of any specific finding about the medication itself.
The FDA's 2024 cardiovascular risk-reduction approval for semaglutide
In March 2024, the FDA approved a new indication for semaglutide 2.4 mg, sold under the brand name Wegovy®, to reduce the risk of cardiovascular death, heart attack, and stroke in adults who already have established cardiovascular disease and either obesity or overweight. The approval was based on a large clinical trial known as SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), which studied semaglutide specifically in people who had already had a cardiac event or been diagnosed with cardiovascular disease.
This was a notable shift because it was the first time a weight-management medication received an FDA indication tied directly to reducing serious cardiovascular events, rather than to weight loss alone. It's worth being precise about scope, though: the approval applies to a defined patient population, people with existing cardiovascular disease who also have obesity or overweight, and not to everyone who takes semaglutide for any reason.
How this differs from the earlier type 2 diabetes cardiovascular data
This 2024 approval is sometimes confused with an earlier, separate cardiovascular finding tied to Ozempic® (semaglutide), which is FDA-approved for type 2 diabetes. Years before the Wegovy® approval, semaglutide had already shown a reduction in cardiovascular risk in adults who had type 2 diabetes and established heart disease, and that data is reflected in Ozempic®'s own FDA-approved labeling for that specific population.
The two findings are related, since both involve semaglutide and cardiovascular outcomes, but they come from different trials, apply to different brand-name products, and describe different, though overlapping, patient populations. Someone with type 2 diabetes and heart disease and someone with obesity, heart disease, and no diabetes are not automatically the same case from a labeling standpoint, even if both may ultimately benefit from treatment as determined by their own clinician.
| Product & approval | Who it applies to |
|---|---|
| Ozempic® (semaglutide), earlier cardiovascular data | Adults with type 2 diabetes and established cardiovascular disease |
| Wegovy® (semaglutide), March 2024 approval | Adults with established cardiovascular disease and obesity or overweight, whether or not they have diabetes |
| Compounded semaglutide or tirzepatide | Not FDA-approved; this cardiovascular indication does not apply |
What this means, and doesn't mean, for compounded and off-label use
It's worth being precise about compounded versions of these medications. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate, such as during an FDA-declared shortage. Because the cardiovascular risk-reduction indication is tied to a specific FDA-approved product, Wegovy®, studied in a specific trial, it does not carry over to compounded formulations, even though they share the same active ingredient. You can read more in what is compounded semaglutide and what is compounded tirzepatide.
The same logic applies to tirzepatide products. Mounjaro® is FDA-approved for type 2 diabetes and Zepbound™ for chronic weight management and, separately, for moderate-to-severe obstructive sleep apnea in adults with obesity; neither currently carries the specific cardiovascular risk-reduction indication that applies to Wegovy®. None of this means tirzepatide has no cardiovascular relevance, only that this particular, FDA-reviewed claim is specific to one product studied in one trial, and shouldn't be generalized beyond that.
Heart rate changes and other cardiovascular considerations to know
Separately from the cardiovascular risk-reduction indication, GLP-1 medications are associated with a modest increase in resting heart rate, which is described in their FDA prescribing information. For most people this change is mild and doesn't require any action beyond what's already part of routine monitoring, but it's one reason your clinician may check your heart rate periodically during treatment, particularly if you have an existing heart rhythm condition.
People with a history of heart failure, arrhythmia, a prior heart attack or stroke, or other cardiovascular conditions should share that history with their prescribing clinician before starting a GLP-1 medication. This isn't because these medications are automatically unsafe for that group, many people with cardiovascular disease are exactly who the 2024 Wegovy® indication is meant to help, but because an individualized evaluation is how a clinician decides whether, and how, to monitor you during treatment. You can read more general context in our guide to side effects of GLP-1 medications.
Supportive habits for heart health during GLP-1 treatment
Your clinician directs your individual treatment plan and any related monitoring, but a few general habits often come up in conversations about heart health during GLP-1 treatment:
- Keep up with routine cardiovascular monitoring, including blood pressure checks and any labs your care team recommends as part of your overall plan.
- Stay consistent with physical activity as approved by your clinician, since regular movement supports cardiovascular health independently of any medication.
- Share your full cardiac history at your first evaluation and update your clinician if anything changes, including new medications from other providers.
- Follow your prescribed dose titration schedule rather than adjusting it on your own; see our guide to what to expect in your first month of GLP-1 treatment for how that typically works.
- Report new or worsening symptoms promptly instead of waiting for a scheduled check-in if something feels off.
None of these habits guarantee a specific cardiovascular outcome, and they aren't a substitute for your prescribed treatment plan. They're general considerations to discuss with your own clinician, who can weigh them against your individual health history.
When to contact your clinician about heart-related symptoms
Contact your clinician promptly, or seek urgent care, if you notice:
- A new or noticeably worsening rapid or irregular heartbeat
- Chest pain or pressure, with or without exertion
- Shortness of breath that's new or getting worse
- New swelling in your legs or ankles
- Fainting or a sense of near-fainting
These symptoms warrant prompt medical evaluation regardless of which medication you're taking, and they should never be worked through on your own while waiting for a routine follow-up.
The bottom line
Heart health and GLP-1 medications intersect in two distinct, well-documented ways: a specific, evidence-based FDA indication for Wegovy® in adults who already have cardiovascular disease and obesity or overweight, and a labeled, generally mild increase in resting heart rate that's part of routine monitoring for anyone on these medications. Understanding which parts of the story apply to your own situation, and sharing your cardiac history with your clinician, is a reasonable part of using any GLP-1 medication responsibly.
You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Semaglutide is FDA-approved as Ozempic® for type 2 diabetes, including a reduction in the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and as Wegovy® for chronic weight management and, since March 2024, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight; tirzepatide is FDA-approved as Mounjaro® for type 2 diabetes and as Zepbound™ for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. A modest increase in resting heart rate has also been reported. These effects are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. These medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about any history of heart failure, arrhythmia, heart attack, stroke, kidney disease, pancreatitis, gallbladder disease, diabetic retinopathy, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Can GLP-1 medications help protect my heart?
In March 2024, the FDA approved semaglutide 2.4 mg (Wegovy®) to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and either obesity or overweight, based on results from a large clinical trial. This is a specific, evidence-based indication for one FDA-approved product in a defined patient population, not a general claim that every GLP-1 medication protects heart health for everyone who takes it.
Is this the same as the earlier heart-related data for Ozempic®?
No. Ozempic® (semaglutide) already carried a separate, earlier FDA-recognized reduction in cardiovascular risk for adults with type 2 diabetes and established heart disease. The 2024 Wegovy® approval is a distinct indication that extends a related benefit to people who have cardiovascular disease and obesity or overweight, whether or not they also have type 2 diabetes.
Does this cardiovascular benefit apply to compounded semaglutide or tirzepatide?
No. This indication is specific to the FDA-approved brand product studied in the trial. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, so this cardiovascular risk-reduction indication does not apply to them, even though they share the same active ingredient.
Can GLP-1 medications affect heart rate?
Yes. A modest increase in resting heart rate has been reported with GLP-1 medications and is described in their FDA prescribing information. Your clinician may check your heart rate as part of routine monitoring during treatment.
Should I tell my clinician about a heart condition before starting a GLP-1 medication?
Yes. Tell your prescribing clinician about any history of heart failure, arrhythmia, heart attack, stroke, or other cardiovascular conditions before starting treatment. This helps them determine whether a GLP-1 medication is an appropriate part of your care plan and how to monitor you during treatment.
What heart-related symptoms should prompt me to contact my clinician?
Contact your clinician promptly, or seek urgent care, if you notice a new or worsening rapid heartbeat, chest pain or pressure, shortness of breath, swelling in your legs or ankles, or fainting. These symptoms need prompt medical evaluation regardless of which medication you are taking.
